On Wednesday, September 30, 2026, Dr. Ali Al-Gamrawi, head of the Egyptian Drug Authority, met with Dr. Yang Xing, deputy commissioner of China's National Medical Products Administration (NMPA). The meeting, attended by Egyptian Ambassador to China Khaled Nazmi and NMPA representatives, aimed to explore ways to enhance cooperation and regulatory coordination between the two countries. This visit marks a significant step in strengthening ties between Egypt and China in the pharmaceutical sector.
During the meeting, Dr. Al-Gamrawi highlighted Egypt's capabilities in the pharmaceutical and vaccine industries, as well as recent developments in the country's regulatory and manufacturing landscape. These advancements have increased the competitiveness of Egypt's pharmaceutical sector and solidified its position as a regional hub for the industry and a gateway to African markets. The Egyptian delegation showcased the country's potential for growth and collaboration in the sector.
Dr. Al-Gamrawi emphasized that Egypt's regulatory and manufacturing developments provide a strong foundation for expanding international cooperation, technology transfer, and capacity building. This cooperation is expected to enhance the sustainability and security of Egypt's pharmaceutical and vaccine supplies. By working together, Egypt and China can leverage each other's strengths to drive progress in the sector.
The two sides discussed opportunities for cooperation in pharmaceutical manufacturing, technology transfer, and the exchange of regulatory best practices. These efforts aim to strengthen institutional coordination between the Egyptian Drug Authority and the NMPA, develop frameworks for joint cooperation, and support partnerships between the two countries in the pharmaceutical sector. This cooperation will help drive innovation and growth in the industry.
The meeting is part of the Egyptian Drug Authority's efforts to enhance cooperation with international regulatory agencies, exchange expertise, and develop regulatory and manufacturing capacities. By fostering partnerships and attracting international investment, Egypt aims to bolster its position as a regional hub for the pharmaceutical industry and a gateway to African markets. This strategic approach will help drive economic growth and improve healthcare outcomes.
The Egyptian-Chinese cooperation is expected to have a positive impact on the country's pharmaceutical sector, enabling the development of new products, improving manufacturing standards, and enhancing regulatory frameworks. This collaboration will also facilitate the transfer of technology and expertise, ultimately contributing to the growth and development of Egypt's pharmaceutical industry. The partnership will be crucial in addressing the country's healthcare needs.
The meeting between Dr. Al-Gamrawi and Dr. Yang Xing marks a significant milestone in Egypt-China relations, demonstrating the two countries' commitment to cooperation in the pharmaceutical sector. By working together, Egypt and China can achieve mutually beneficial outcomes, drive innovation, and improve healthcare outcomes for their citizens. The partnership is poised to yield positive results, enhancing the security and sustainability of pharmaceutical supplies in Egypt and beyond.
Key points
- Egypt and China discuss enhancing cooperation in pharmaceutical sector
- Egyptian Drug Authority chief meets with Chinese counterpart to boost regulatory cooperation
- Partnership aims to drive innovation, growth, and healthcare improvements in Egypt's pharmaceutical sector
